Decreased IFIT2 Expression Promotes Gastric Cancer Progression and Predicts Poor Prognosis of the Patients
Decreased IFIT2 Expression Promotes Gastric Cancer Progression and Predicts Poor Prognosis of the Patients
复制标题
IFIT2表达下降促进胃癌进展并预测患者预后不良
DOI：
10.1159/000486219
复制
发表时间：
2018-01-01
影响因子：
--
通讯作者：
Jiang, Jingting
中科院分区：
文献类型：
--
作者：
Chen, Lujun;Zhai, Wensi;Jiang, Jingting
背景/目的：干扰素信号通路的状态已被证明与免疫检查点阻断治疗晚期人类癌症的反应密切相关。干扰素诱导蛋白结合四肽重复序列2(IFIT2)，又称干扰素刺激基因54(ISG54)，是一种高度敏感的ISGs，能抑制肿瘤细胞的增殖和迁移，调节病毒复制，从而达到抗癌、抗病毒的作用。在本研究中，我们旨在探讨IFIT2在人胃癌中的作用。方法：采用免疫组织化学方法检测IFIT2在胃癌组织中的表达与胃癌患者临床参数的关系。利用RNAi技术对IFIT2基因进行敲除，以评估IFIT2在调节人胃癌细胞系生物学行为中的作用。结果：IFIT2在胃癌组织中的表达与肿瘤分期及术后预后密切相关。此外，人胃癌细胞株SGC7901和AgS细胞中IFIT2表达降低，细胞存活率、迁移能力和S期细胞比例显著增加。结论：IFIT2的低表达可促进胃癌的进展，预测患者的不良治疗效果。
Background/Aims: The status of interferon (IFN) signaling pathway has been shown to be closely associated with the response of immune checkpoint blockade therapy against advanced human cancers. IFN-induced protein with tetratricopeptide repeats 2 (IFIT2), also known as IFN-stimulated gene 54 (ISG54), is one of the most highly responsive ISGs, which can inhibit the proliferation and migration of cancer cells, and regulate viral replication, resulting in anti-cancer and anti-viral effects. In the present study, we aimed to investigate the role of IFIT2 in human gastric cancer. Methods: Immunohistochemistry assay was used to investigate the correlation between the IFIT2 expression in cancer tissues and clinical parameters of gastric cancer patients. Knockdown of IFIT2 was performed using RNAi to assess the role of IFIT2 in the regulation of biological behaviors in human gastric cancer cell lines. Results: IFIT2 expression in gastric cancer tissues was significantly associated with tumor stage and postoperative prognoses of the patients. Moreover, decreased IFIT2 expression in human gastric cancer cell lines SGC-7901 and AGS significantly increased the cell viability, cell migration and the ratios of cells in S phase. Conclusion: Our present study demonstrated that the decreased IFIT2 expression could promote the gastric cancer progression and predict poor therapeutic outcomes of the patients.